NEW YORK (GenomeWeb) — Invitae announced today that it is partnering with RNAi therapeutics firm Alnylam Pharmaceuticals to provide free genetic testing to improve diagnosis and management of a rare inherited disorder called primary hyperoxaluria.
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?Login Now.
Don't have a 360Dx or GenomeWeb account?Register for Free.
This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.